An interventional study of Lubiprostone and Placebo in Irritable Bowel Syndrome and Constipation, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-27.
Sponsored by University of Michigan · Not applicable and Interventional
Irritable bowel syndrome (IBS) is a common disorder which presents with abdominal pain or discomfort in association with altered bowel habit. IBS is further subcategorized as three types according to the predominant bowel movement pattern: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed-IBS (IBS-M). The exact causes of IBS remain incompletely understood, but proposed mechanisms include abnormal motility, visceral hypersensitivity, abnormal brain-gut interactions, psychological distress, and altered GI tract motility.
Lubiprostone, a novel drug that works by activating the colonic Chloride channel type 2(ClC-2), has been approved for use in patients with chronic idiopathic constipation and recently approved for the treatment of IBS-C in women aged 18 and older. By activating the ClC-2 chloride channel in the colon, lubiprostone allows more fluid secretion into the intestinal lumen which leads to softer stool consistency. In phase III clinical trials, patients with IBS-C receiving lubiprostone have reported improvements in many symptoms such as abdominal pain and constipation. However, there is limited physiologic data to explain how exactly lubiprostone improves IBS-C symptoms.
The Smartpill is a novel non-digestible capsule that is capable of measuring intraluminal pH, pressure, and temperature in the gastrointestinal (GI) tract. Smartpill has been shown to accurately measure whole gut as well as regional (i.e. stomach, small bowel, colon) transit time.
The primary aim of this study is to determine the effects of lubiprostone on whole GI tract transit, colonic transit, motility, and intraluminal pH in patients with IBS-C through evaluation with the Smartpill. The investigators propose to study the effect of lubiprostone vs. placebo on these parameters, and secondarily to evaluate changes in these parameters with differing doses of lubiprostone.
The investigators hypothesize that lubiprostone will increase whole GI and colonic transit compared to placebo in patient with IBS. the investigators do not expect a change in intraluminal pH with lubiprostone compared to placebo.
1,084 studies on the registry are indexed under Irritable Bowel Syndrome; 196 are open to participants now.
This study's enrollment of 60 is below the median of 70 across 869 interventional studies indexed under Irritable Bowel Syndrome.
Browse Irritable Bowel Syndrome studies →University of Michigan is the lead sponsor of 1,503 studies on the registry; 189 are open to participants now.
Of its 167 completed or terminated interventional studies of FDA-regulated products, 132 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet Rome III criteria for IBS[2]:
Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with 2 or more of the following:
Fulfill the Rome III stool consistency criteria for IBS-C[2]
Females of childbearing potential must use an effective means of contraception during the course of the study
Exclusion Criteria:
IBS with diarrhea (IBS-D)
Mixed IBS (IBS-M)
Unsubtyped IBS
1. Insufficient abnormality of stool pattern to meet criteria for IBS-C, IBS-D or IBS-M
Failure of balloon expulsion test
Use of drugs known to affect gastrointestinal motility
Laxatives (stable doses of fiber taken for minimum of 4 weeks will be allowed)
Osmotic laxatives:
Magnesium hydroxide, Polyethylene glycol,Lactulose, Sorbitol
Stimulant laxatives:
Bisacodyl, Anthraquinones (senna), Misoprostol
Prokinetic agents:
Metoclopramide, domperidone, erythromycin
Anti-diarrheal agents:
Loperamide, Diphenoxylate, Bismuth
Anti-spasmotics:
Dicyclomine, Hyoscyamine
Opioid, narcotic, opioid/narcotic-containing analgesics:
Morphine, Hydrocodone, Codeine, Methadone, Propoxyphene
Comorbid medical problems that may affect gastrointestinal transit or motility
Current or recent history (within last 6 months) of:
Diverticulitis, Duodenal or gastric ulcer, Acute pancreatitis, Ileus
Cardiac pacemaker, defibrillator, or other implanted electromagnetic device, Known Zenker's diverticulum, Dysphagia
Drug: Lubiprostone · Other: Smartpill wireless motility capsule
Drug: Lubiprostone · Other: Smartpill wireless motility capsule
Drug: Placebo · Other: Smartpill wireless motility capsule
lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
taken orally for 28 days
Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline
Change in gastric emptying time, small bowel transit time, colon transit time and whole gut transit time measured in hours based on a measurement done at baseline and then again at 3 weeks into the intervention within each treatment arm
Time frame: 21-28 days
Change in Small Bowel pH and Colon pH From Baseline
Change in the mean pH of the small intestine and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.
Time frame: 21-28 days
Change in Motility Pattern of the Small Bowel and Colon From Baseline as Defined by the Motility Index
Change in the motility index defined as the natural log \[(sum of pressure amplitudes times the number of contractions) + 1\] for the small bowel and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.
Time frame: 21-28 days
| Milestone | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID |
|---|---|---|---|
| Started | 18 | 17 | 17 |
| Completed | 17 | 16 | 17 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
Change in gastric emptying time, small bowel transit time, colon transit time and whole gut transit time measured in hours based on a measurement done at baseline and then again at 3 weeks into the intervention within each treatment arm
| hours | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID |
|---|---|---|---|
| Gastric emptying time | 5.49 ± 13.77 | 6.52 ± 15.33 | -0.16 ± 3.17 |
| Small bowel transit time | 0.2 ± 2.04 | 0.15 ± 1.78 | -0.001 ± 2.68 |
| Colon transit time | 5.75 ± 21.23 | -4.43 ± 44.6 | 2.59 ± 31.15 |
| Whole gut transit time | 10.32 ± 27.3 | -1.74 ± 42.67 | 1.67 ± 29.73 |
Change in the mean pH of the small intestine and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.
| pH | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID |
|---|---|---|---|
| Small bowel pH | 0.18 ± 0.37 | 0.23 ± 0.36 | 0.24 ± 0.4 |
| Colon pH | -0.03 ± 0.50 | -0.07 ± 0.45 | 0.27 ± 0.56 |
Change in the motility index defined as the natural log \[(sum of pressure amplitudes times the number of contractions) + 1\] for the small bowel and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.
| units on a scale | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID |
|---|---|---|---|
| Small bowel motility index | 0.06 ± 1.37 | -0.01 ± 1.89 | 0.6 ± 2.36 |
| Colon motility index | -0.34 ± 1.96 | -1.32 ± 1.97 | 0.17 ± 1.72 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/18 (11.1%) | 9/18 (50%) |
| Lubiprostone 24 mcg QD | — | 0/17 (0%) | 11/17 (64.7%) |
| Lubiprostone 8 mcg BID | — | 0/17 (0%) | 10/17 (58.8%) |
| Event | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID |
|---|---|---|---|
| DehydrationCardiac disorders | 1/18 | 0/17 | 0/17 |
| Atrial fibrillationCardiac disorders | 1/18 | 0/17 | 0/17 |
| Event | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 2/18 | 6/17 | 4/16 |
| NauseaGastrointestinal disorders | 4/18 | 6/17 | 6/17 |
| FlatulenceGastrointestinal disorders | 4/18 | 2/17 | 4/17 |
| Abdominal painGastrointestinal disorders | 2/18 | 4/17 | 2/17 |
| Abdominal distentionGastrointestinal disorders | 0/18 | 2/17 | 4/17 |
| VomitingGastrointestinal disorders | 0/18 | 3/17 | 0/17 |
| HeadacheGeneral disorders | 1/18 | 2/17 | 2/17 |
| Chest discomfortRespiratory, thoracic and mediastinal disorders | 0/18 | 0/17 | 1/17 |
| DizzinessNervous system disorders | 1/18 | 1/17 | 1/17 |
| Respiratory infectionRespiratory, thoracic and mediastinal disorders | 1/18 | 0/17 | 1/17 |
The baseline data is given for those persons who actually completed the study, so the two people who dropped out were not included in the baseline measures. We determined this to be the more useful way to identify the effects of the three randomized procedures. Therefore the baseline data is based on the 50 participants who completed the study.
| Age, Customized(years) | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID | Total |
|---|---|---|---|---|
| mean age | 39.9 ± 16.1 | 46.5 ± 18.7 | 37.2 ± 15.8 | 41.2 ± 17.2 |
| Gender(Participants) | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID | Total |
|---|---|---|---|---|
| Female | 16 | 15 | 13 | 44 |
| Male | 1 | 1 | 4 | 6 |
| Region of Enrollment(participants) | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID | Total |
|---|---|---|---|---|
| United States | 17 | 16 | 17 | 50 |
| Baseline gastric emptying time(hours) | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID | Total |
|---|---|---|---|---|
| Mean | 4.25 ± 5.52 | 3.18 ± 0.95 | 4.67 ± 3.47 | 4.01 ± 3.74 |
| Baseline Small Bowel Transit time(hours) | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID | Total |
|---|---|---|---|---|
| Mean | 4.84 ± 1.69 | 4.01 ± 1.02 | 4.81 ± 2.13 | 4.63 ± 1.75 |
| Baseline Colon Transit Time(hours) | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID | Total |
|---|---|---|---|---|
| Mean | 32.18 ± 16.46 | 44.61 ± 27.18 | 37.12 ± 30.04 | 38.15 ± 25.31 |
| Baseline Whole Gut Transit Time(hours) | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID | Total |
|---|---|---|---|---|
| Mean | 41.47 ± 16.26 | 51.81 ± 26.78 | 47.0 ± 30.0 | 47.0 ± 24.97 |
| Baseline Small Bowel pH(units on pH scale) | Placebo | Lubiprostone 24 mcg QD | Lubiprostone 8 mcg BID | Total |
|---|---|---|---|---|
| Mean | 6.82 ± 0.28 | 6.75 ± 0.34 | 6.77 ± 0.39 | 6.78 ± 0.33 |
3 further baseline measures are reported on the registry.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lubiprostone